ClinicalTrials.Veeva

Menu

Evaluating Positron Emission Mammography Imaging of Suspicious Breast Abnormalities

University Health Network, Toronto logo

University Health Network, Toronto

Status

Completed

Conditions

Breast Cancer

Treatments

Device: Performance of R-PEM

Study type

Interventional

Funder types

Other

Identifiers

NCT03520218
18-5029

Details and patient eligibility

About

The goal of this pilot project is to test the new Radialis Positron Emission Mammography (R-PEM) system in breast cancer patients that has a higher sensitivity with lower radiation doses than conventional PET/CT.

The plan for the pilot study is to image patients who are already scheduled for diagnostic imaging for breast cancer after a positive core biopsy. Participants will be injected with 5mCi (millicurie) of F18-Fluorodeoxyglucose (FDG) and patient will wait for a couple of hours for uptake of FDG. After this time, the first R-PEM scan will occur. Additional optional R-PEM scans can be performed 4 hours after injection and 7 hours after injection with reductions in radiation emission.

Additionally, R-PEM images will be compared to standard-of-care breast Magnetic Resonance Imaging (MRI) and digital breast tomosynthesis (DBT) to study extension of disease and screening of contralateral breast.

Enrollment

25 patients

Sex

Female

Ages

26+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject is female of any race and ethnicity
  • Subject is at least 26 years old
  • Following routine mammography imaging, subject is categorized as BI-RADS score 4C or 5 because of calcifications, masses, asymmetries or/and architectural distortion will undergo additional tests including biopsy within 30 days of routine imaging
  • Subject is female with a recent breast biopsy confirming breast cancer

Exclusion criteria

  • Subject unable or unwilling to undergo informed consent
  • Subjects who are unable or unwilling to tolerate any of the imaging tests because of claustrophobia, compression, etc.
  • Subjects who are pregnant or who think they may be pregnant
  • Subjects who are breast-feeding
  • Subjects weight exceed table limits of MRI and PET-CT (300-450 lb or 135-205 kg)
  • Subjects with history of allergic reaction to gadolinium or previous history of life-threatening anaphylactic reaction to any contrast.
  • Claustrophobic subjects

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

25 participants in 1 patient group

Performance of R-PEM
Experimental group
Description:
5mCi of F-18 FDG will be injected and patients will wait for uptake of FDG before proceeding with first set of R-PEM scans. Additional optional R-PEM scans may be performed 4 hours after injection, and then possibly 7 hours after injection. These R-PEM images will be compared to standard diagnostic breast work-up using DBT and MRI
Treatment:
Device: Performance of R-PEM

Trial contacts and locations

1

Loading...

Central trial contact

Anabel Scaranelo

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems